BRPI0815020A2 - Composto, e, métodos de aliviar um efeito colateral de um opiato em um paciente que recebeu um opiato, e de melhorar função do intestino pós-operatório em um paciente que se submeteu a cirurgia. - Google Patents

Composto, e, métodos de aliviar um efeito colateral de um opiato em um paciente que recebeu um opiato, e de melhorar função do intestino pós-operatório em um paciente que se submeteu a cirurgia.

Info

Publication number
BRPI0815020A2
BRPI0815020A2 BRPI0815020-6A2A BRPI0815020A BRPI0815020A2 BR PI0815020 A2 BRPI0815020 A2 BR PI0815020A2 BR PI0815020 A BRPI0815020 A BR PI0815020A BR PI0815020 A2 BRPI0815020 A2 BR PI0815020A2
Authority
BR
Brazil
Prior art keywords
opiat
patient
reliefing
operative
composition
Prior art date
Application number
BRPI0815020-6A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Mark P Wentland
Original Assignee
Rensselaer Polytech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytech Inst filed Critical Rensselaer Polytech Inst
Publication of BRPI0815020A2 publication Critical patent/BRPI0815020A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0815020-6A2A 2007-08-09 2008-08-08 Composto, e, métodos de aliviar um efeito colateral de um opiato em um paciente que recebeu um opiato, e de melhorar função do intestino pós-operatório em um paciente que se submeteu a cirurgia. BRPI0815020A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95496007P 2007-08-09 2007-08-09
PCT/US2008/072632 WO2009023567A1 (en) 2007-08-09 2008-08-08 Quaternary opioid carboxamides

Publications (1)

Publication Number Publication Date
BRPI0815020A2 true BRPI0815020A2 (pt) 2015-03-10

Family

ID=39941437

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815020-6A2A BRPI0815020A2 (pt) 2007-08-09 2008-08-08 Composto, e, métodos de aliviar um efeito colateral de um opiato em um paciente que recebeu um opiato, e de melhorar função do intestino pós-operatório em um paciente que se submeteu a cirurgia.

Country Status (14)

Country Link
US (4) US8263807B2 (esLanguage)
EP (1) EP2190819B1 (esLanguage)
JP (1) JP5581211B2 (esLanguage)
KR (1) KR101519682B1 (esLanguage)
CN (1) CN101827819B (esLanguage)
AU (1) AU2008286979B2 (esLanguage)
BR (1) BRPI0815020A2 (esLanguage)
CA (1) CA2694497C (esLanguage)
EA (1) EA020658B1 (esLanguage)
ES (1) ES2586245T3 (esLanguage)
IL (1) IL203459A (esLanguage)
MX (1) MX2010001371A (esLanguage)
NO (1) NO341089B1 (esLanguage)
WO (1) WO2009023567A1 (esLanguage)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275004A (zh) 2007-11-30 2013-09-04 普渡制药公司 苯并吗啡烷化合物
EP3170395A1 (en) * 2009-03-19 2017-05-24 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
ES2729679T3 (es) 2009-12-04 2019-11-05 Alkermes Pharma Ireland Ltd Derivados de morfinano para el tratamiento de la sobredosis de fármacos
WO2011119605A2 (en) * 2010-03-22 2011-09-29 Rensselaer Polytechnic Institute Carboxamide biosiosteres of opiates
WO2012005795A1 (en) * 2010-07-08 2012-01-12 Alkermes, Inc. Process for the synthesis of substituted morphinans
EP2407469A1 (en) * 2010-07-13 2012-01-18 Chemo Ibérica, S.A. Salt of sitagliptin
ES2705726T3 (es) 2010-08-23 2019-03-26 Alkermes Pharma Ireland Ltd Métodos para tratar el aumento de peso inducido por antipsicóticos
US20120245193A1 (en) * 2011-02-14 2012-09-27 Alkermes, Inc. PERIPHERIALLY ACTING μ OPIOID ANTAGONISTS
MX2013010027A (es) * 2011-03-03 2014-02-11 Cadila Healthcare Ltd Sales novedosas de inhibidor de la dipeptidil peptidasa iv (dpp-iv).
WO2012138888A1 (en) * 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
EP2725908B1 (en) 2011-06-29 2017-05-31 Alkermes, Inc. Peripherally acting opioid compounds
US9096606B2 (en) 2011-12-08 2015-08-04 Purdue Pharma, L.P. Quarternized buprenorphine analogs
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
ES2692771T3 (es) 2011-12-15 2018-12-05 Alkermes Pharma Ireland Limited Samidorfano (ALKS 33) en combinación con buprenorfina para el tratamiento de trastornos depresivos
US20140066475A1 (en) 2012-09-04 2014-03-06 Euro-Celtique S.A. Method For Treating Pruritus
JP2016519161A (ja) 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
US20160243112A1 (en) * 2015-02-25 2016-08-25 Alkermes, Inc. Treatments for alzheimer's related diseases and disorders
TW202140009A (zh) * 2020-02-13 2021-11-01 大陸商上海翰森生物醫藥科技有限公司 ３－甲醯胺基－４－羥基納曲酮氘代衍生物、其製備方法及其在醫藥上的應用
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
CN115521317B (zh) * 2021-02-02 2025-07-25 山东新时代药业有限公司 一种制备纳呋拉啡中间体的方法
WO2025104754A1 (en) * 2023-11-17 2025-05-22 Msn Laboratories Private Limited, R&D Center A process for the preparation of samidorphan and its intermediates
CN118598813B (zh) * 2024-08-08 2024-10-29 山东齐都药业有限公司 L-苹果酸萨米多芬及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES252980A1 (es) * 1958-10-30 1960-11-01 Boehringer Sohn Ingelheim Procedimiento para la obtencion de nuevas sales cuaternarias, terapéuticamente valiosas, de la normorfina y de sus derivados
DE2254298A1 (de) * 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
GB1511319A (en) * 1974-09-20 1978-05-17 Sterling Drug Inc 2,6-methane-3-benzazocine derivatives and their preparation
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
FR2514644A1 (fr) 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
CA1315689C (en) * 1987-09-03 1993-04-06 Leon I. Goldberg Quarternary derivatives of noroxymorphone which relieve nausea and emesis
TR199801348T2 (xx) * 1996-01-10 1998-10-21 Smithkline Beecham S.P.A. Heterosikl-kondanse morfinoid t�revleri(II).
ES2121553B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion.
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan
WO2001013909A2 (en) * 1999-08-25 2001-03-01 Cooper Barrett R Compositions and methods for treating opiate intolerance
NZ518562A (en) * 1999-11-29 2005-04-29 Adolor Corp Novel methods and compositions involving opioids and antagonists thereof
ES2572332T3 (es) * 2000-10-31 2016-05-31 Rensselaer Polytech Inst 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
BR0314488A (pt) * 2002-09-25 2005-08-02 Euro Celtique Sa Composto, composição farmacêutica e métodos de tratamento
PT1562953E (pt) * 2002-11-08 2009-11-19 Mallinckrodt Inc Processo para a preparação de sais quaternários de n -alquilmorfinano
BRPI0517091B8 (pt) 2004-11-05 2021-05-25 Rensselaer Polytech Inst composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
WO2007014137A2 (en) 2005-07-21 2007-02-01 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
US8163701B2 (en) * 2005-08-19 2012-04-24 Signature Therapeutics, Inc. Prodrugs of active agents

Also Published As

Publication number Publication date
JP2010535814A (ja) 2010-11-25
CA2694497C (en) 2016-07-12
HK1141295A1 (zh) 2010-11-05
ES2586245T3 (es) 2016-10-13
NO20100289L (no) 2010-03-02
KR20100053627A (ko) 2010-05-20
EA201070237A1 (ru) 2010-10-29
US20090197905A1 (en) 2009-08-06
AU2008286979A1 (en) 2009-02-19
US8263807B2 (en) 2012-09-11
MX2010001371A (es) 2010-03-10
US20140107143A1 (en) 2014-04-17
CN101827819B (zh) 2013-06-12
IL203459A (en) 2016-02-29
US8563572B2 (en) 2013-10-22
EP2190819A1 (en) 2010-06-02
US20170095469A1 (en) 2017-04-06
CN101827819A (zh) 2010-09-08
EA020658B1 (ru) 2014-12-30
KR101519682B1 (ko) 2015-05-19
JP5581211B2 (ja) 2014-08-27
CA2694497A1 (en) 2009-02-19
WO2009023567A1 (en) 2009-02-19
AU2008286979B2 (en) 2013-03-28
US20120302594A1 (en) 2012-11-29
EP2190819B1 (en) 2016-05-25
NO341089B1 (no) 2017-08-21

Similar Documents

Publication Publication Date Title
BRPI0815020A2 (pt) Composto, e, métodos de aliviar um efeito colateral de um opiato em um paciente que recebeu um opiato, e de melhorar função do intestino pós-operatório em um paciente que se submeteu a cirurgia.
IL262236B (en) Systems and methods for ex vivo organ care
IL212856A (en) Human antibodies against human tissue factor, conjugates and uses thereof
BRPI0817018A2 (pt) Ferramenta para inserção cirúrgica, combinação de ferramenta com uma extensão de um implante, e, método para implantar um implante em um paciente
BRPI0807908A2 (pt) Melhoramentos em composições medicinais.
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0807208A2 (pt) Aparelho de iluminação portátil afixável em instrumentos cirúrgicos.
BRPI0819980A2 (pt) Conjunto e método de sutura
EP1978865A4 (en) DEVICE FOR PENETRATION OF FABRICS
BRPI0718146A2 (pt) Dispositivos de infusão e métodos
EP2211725A4 (en) SUTURE PASSING INSTRUMENT AND METHOD
BRPI0717732A2 (pt) Guia cirúrgica para implante dental e métodos para o mesmo
ZA200605398B (en) Tibial insert and associated surgical method
EP2099372A4 (en) OSTEOTOMY GUIDANCE AND METHOD FOR CUTTING THE MEDIAL DISTAL TIBIA THEREWITH
BRPI0810554A2 (pt) Implante dentário e conexão de componente dentário
BRPI0817437A2 (pt) Implante cirúrgico com um recurso antirretrocesso
BRPI0814102A2 (pt) Implante pélvico, e, kit.
BRPI0906099A2 (pt) "método de tratamento do câncer em um indivíduo"
EP2139423A4 (en) SURGICAL PACKAGE AND BOWL
DE602007009790D1 (de) Inzisionsinstrument, Inzisionsvorrichtung und Block
SI2548577T1 (sl) Človeška protitelesa proti il-23, sestavki, postopki in uporabe
BR112012001467A2 (pt) instrumentos cirúrgicos para seccionar cavidades em canais intramedulares.
EP2046206A4 (en) SURGICAL INSTRUMENTS
IL198400A0 (en) Surgical cutting devices and methods
BRPI0819642A2 (pt) Método para a formação de uma dentadura para um paciente em uma única visita, e, dentadura

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE N?O FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL